NIFTY 50

Pfizer-BioNTech vaccine trial: US FDA publishes positive initial analysis

Updated : December 09, 2020 19:11:10 IST

Pfizer and AstraZeneca have released additional data from their trials on the efficacy of the vaccines.

The US drug regulator has released its positive initial analysis on the Pfizer-BioNTech vaccine saying the two-dose vaccine is "highly effective" in preventing symptomatic COVID-19.

Key analysis was that the vaccine starts providing protection 10 days after the first dose itself. It is at least 52 percent effective before the second dose, meaning even if people miss their second dose they may get some protection from transmission although how long this immunity will last is still unclear.

CNBC-TV18’s Archana Shukla brings more details.

Watch this video for more.

Click Here:  For the latest news and updates on COVID-19
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV

recommended for you